老年人反复接种与感染后SARS-CoV-2 T细胞交叉反应与多功能反应持久维持
该纵向队列研究追踪65–80岁健康老年人至多六剂mRNA疫苗接种及重复感染,发现三剂后CD4与CD8刺突特异性T细胞反应的数量与质量在2.5年内保持稳定;约60%参与者报告至少一次感染;T细胞对Omicron变异株交叉反应良好,而中和抗体对新型变异株滴度降低。
要点
- 健康老年人接种三剂后刺突特异性T细胞反应数量与质量可稳定维持2.5年。
- T细胞对Omicron变异株显示交叉反应,CD4反应与原始株强相关。
- 中和抗体对新型变异株滴度降低,提示脆弱人群可能需要更新疫苗。
核心结论
- 健康老年人刺突特异性T细胞反应的数量与质量在数年及三剂原始疫苗后得以维持。
- 原始B.1疫苗诱导的T细胞对未来变异株具有良好交叉反应性。
- 中和抗体更具株特异性,对新型变异株中和能力降低,与免疫印记和抗原漂移一致。
研究设计与样本
- 覆盖至多六剂mRNA疫苗接种,接种与感染记录来自国家健康登记和问卷。
主要发现
- 三剂疫苗后CD4和CD8刺突特异性T细胞反应的数量与质量在研究期2.5年内保持稳定。
- 约60%参与者在研究期间报告至少一次感染。
- 2022年初样本对新兴Omicron变异株(XBB.1.5/BA.2.86)显示交叉反应,CD4 T细胞反应在新近SARS-CoV-2毒株与B.1之间强相关。
- 针对B.1的中和抗体滴度保持较高,但对新变异株降低。
- 刺突IgG水平随时间趋于平台,膜蛋白IgG水平揭示未报告的感染。
临床怎么用
- 健康老年人总体具有稳健的细胞免疫保护以预防重症COVID-19。
- 对脆弱个体,更新疫苗可能仍是必要的。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Understanding humoral and T cell responses to SARS-CoV-2 immunisations is important for informing seasonal COVID-19 vaccine recommendations in the elderly. Existing protection against emerging strains may vary based on vaccination and infection history. Using a longitudinal cohort of healthy seniors (65-80 years), we investigated the magnitude and quality of T cell and antibody responses after multiple SARS-CoV-2 vaccine doses and repeated infections. METHODS: Samples were collected at six consecutive time points from Dec 2020 to May 2024, covering up to six doses of mRNA vaccines. Vaccination and infection records were retrieved from national health registries and questionnaires. Frequency and polyfunctionality of T cell responses and neutralising antibodies (NAbs) to the B.1 strain and several Omicron variants were determined, as well as anti-spike, -nucleocapsid, and -membrane protein IgG levels. FINDINGS: After three vaccine doses, the quantity and quality of CD4 and CD8 spike-specific T cell responses remained stable throughout the study period spanning 2.5 years and up to three additional booster doses. About 60% of participants reported at least one infection over this time period. Samples from early 2022 showed cross-reactivity to emerging Omicron variants (XBB.1.5/BA.2.86) and CD4 T cell responses strongly correlated between newer SARS-CoV-2 strains and B.1. By contrast, NAb titres against B.1 remained high but were reduced against newer variants. Spike IgG levels plateaued over time while membrane protein IgG levels revealed unreported infections. INTERPRETATION: The quality and quantity of spike-specific T cell responses were maintained over several years and three doses of the original B.1 vaccine generated good T cell cross-reactivity against future strains. This suggests that overall, healthy older adults have robust cellular protection against severe COVID-19. NAbs were more strain-specific with reduced neutralisation of newer variants, consistent with immune imprinting and antigenic drift, suggesting that updated vaccines may be necessary for vulnerable individuals.
引用
- Robertson AH, Wolf AS, Fossum E, et al. Long-lasting cross-reactive and polyfunctional SARS-CoV-2 T cell responses in seniors are maintained after repeated vaccination and infections. Vaccine. 2026. PMID: 41895154. doi:10.1016/j.vaccine.2026.128511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。